Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berobenatide in Knee Osteoarthritis and Overweight/Obesity (VESPER-OA 2)
NCT07915609Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 3 trial of berobenatide in osteoarthritis (OA), obesity, sponsored by Pfizer. Started Oct 2026; status: recruiting.
02
Drugs
berobenatide
03
Conditions
osteoarthritis (OA)obesity
Beyond the preview
Go deeper on NCT07915609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915609.